Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1510643
European Journal of Endocrinology, Vol 151, Issue 6, 643-655
Copyright © 2004 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krantic, S
Right arrow Articles by Enjalbert, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krantic, S
Right arrow Articles by Enjalbert, A

Articles

Novel modalities of somatostatin actions

S Krantic, I Goddard, A Saveanu, N Giannetti, J Fombonne, A Cardoso, P Jaquet, and A Enjalbert

Interactions Cellulaires Neuroendocriniennes (ICNE), Unite Mixte de Recherche (UMR 6544), Centre National de Recherche Scientifique (CNRS)/Universite de la Mediterranee, Institut Jean Roche, Faculte de Medecine Nord, 13916, Marseille, France.

The first part of this contribution reviews the current knowledge about endocrine and neuromodulatory actions of somatostatin. These biological actions are exerted according to endocrine, paracrine and autocrine modes of action and involve five distinct types of membrane receptors belonging to the 'super-family' of G-protein-coupled receptors.A new concept concerning a juxtacrine mode of action has recently been introduced to refer to the intervention of cytokines and growth factors in direct, cell-to-cell communication. The evidence in favor of juxtacrine actions of somatostatin will be presented in the second part of this review and illustrated by our own results on macrophage-lymphocyte T interactions in the immune system and spermatogonia-Sertoli cell interactions in mammalian testis. Another phenomenon such as ligand-induced somatostatin receptor homo- and hetero-dimerization resulting in 'poly'-receptors (with characteristics different from those of each of the two receptors forming the complex) is also at the origin of a novel mode of somatostatin action. The latter will be illustrated by the data obtained on human pituitary adenomas with somatostatin analogs specific for either 'poly'-receptor or relevant individual receptors.The arguments in favor of the analogous mode of actions among different families of chemical messengers such as peptides, cytokines and growth factors are discussed in the concluding section. The emerging unifying concepts on such functional analogies might provide a useful basis for the development of synthetic analogs not only for bioactive peptides but also for other types of chemical messengers.


This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. L. Hagemeister and M. A. Sheridan
Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R490 - R497.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
N. Kimura, N. Takamatsu, Y. Yaoita, R Y. Osamura, and N. Kimura
Identification of transcriptional regulatory elements in the human somatostatin receptor sst2 promoter and regions including estrogen response element half-site for estrogen activation
J. Mol. Endocrinol., February 1, 2008; 40(2): 75 - 91.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
C. Armani, E. Catalani, A. Balbarini, P. Bagnoli, and D. Cervia
Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages
J. Leukoc. Biol., March 1, 2007; 81(3): 845 - 855.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 European Society of Endocrinology.